About Inflammatix
Inflammatix makes rapid blood tests for emergency clinicians treating adults with suspected acute infections or sepsis. Its TriVerity test reads the body's immune response to show infection type and the chance of severe illness. Those results can guide treatment and further testing. They can also inform admission or discharge.
Inflammatix is based in Sunnyvale, California. Co-founder Tim Sweeney is CEO, and Purvesh Khatri is co-founder and chief scientist. Its partners include NIH, BARDA, and DARPA. DRIVe is also a partner. It is building partnerships with diagnostic-instrument, companion-therapy, and distribution companies worldwide.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Apr 5, 2024 | Nov 19, 2026 | $47,421,597of $57.2M target | 14 | $3.3M | Equity, Options, Securities on exercise, Offer and sale of Series E and E-1 Preferred Stock and Common Stock issuable upon conversion thereof. Certain exchanged Common Stock were issued for shares of a specific series of Preferred Stock. Warrants to purchase Series E-2 Preferred Stock.Rule 506(b) | Form D ↗ |
| Mar 15, 2021 | Mar 24, 2021 | $102,396,088fully sold | 8 | $12.7M | EquityRule 506(b) | Form D ↗ |
| Jan 9, 2020 | Feb 3, 2020 | $32,072,827fully sold | 6 | $5.3M | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $181,890,512 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Inflammatix's Form D filed Nov 19, 2026.


- Singulex, director: May 23, 2011 · Aug 5, 2011 (amended) · Mar 15, 2012 · Jun 7, 2013
- Ixcela, director: Jul 26, 2017 · Nov 29, 2017 (amended)
- Inflammatix, director: Nov 19, 2026

- Selux Diagnostics, director: Feb 13, 2024
- Scipher Medicine, director: Jul 30, 2024
- Inflammatix, operating partner at northpond ventures and director: Nov 19, 2026


- Inflammatix, co-founder and director: Feb 3, 2020 · Nov 19, 2026
- Piction Health, director: Jun 26, 2024

- Cepheid, executive officer and director: Jan 28, 2013
- Inflammatix, EVP/chief medical officer, cepheid and director: Feb 3, 2020 · Mar 24, 2021 · Nov 19, 2026
Earlier filings also listed
- Michael Rubin · directorLast listed on the Form D that Inflammatix filed on March 24, 2021; on 2 of its 3 filings.
- Kenneth Bahk · directorLast listed on the Form D that Inflammatix filed on March 24, 2021; on 2 of its 3 filings.
- Justin Kao · directorLast listed on the Form D that Inflammatix filed on March 24, 2021; on 1 of its 3 filings.
Who Invested in Inflammatix
Scroll table to see all columns →
| Announced | Round | Amount | Lead | Other investors | On the Form D | Source |
|---|---|---|---|---|---|---|
| Sep 12, 2024 | Series E | $57 million | Khosla Ventures; Think.Health | Northpond Ventures, D1 Capital Partners, Iberis Capital, Vesalius BioCapital, OSF Healthcare, RAW Ventures, and others | First sale Apr 5, 2024, about 5.3 months before the announcement; $47,421,597 of $57,272,732 from 14 investors. [11] | [7] |
Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
Why Investors Backed Inflammatix
Hospitals see 20 million people each year with suspected acute infection or sepsis. Khosla Ventures chose Inflammatix because its approach finds immune-cell changes before obvious symptoms, which may allow clinicians to act sooner. [7]
“TriVerity is bringing the promise of machine learning and AI to infection and sepsis care.”
Origin and Team
TriVerity came from Stanford University research by co-founders Tim Sweeney and Purvesh Khatri. Inflammatix holds exclusive rights to the core intellectual property. During surgical training, Sweeney became frustrated with infection diagnostics and worked with Khatri on algorithms for varied large datasets. Khatri created Onto-Express, an open-access tool for analyzing gene-activity data. [2][6]
Product and Technology
TriVerity measures 29 gene signals in blood. Machine-learning models convert those signals into bacterial, viral, and illness-severity scores in about 30 minutes. Its disposable cartridge runs on the Myrna benchtop instrument, which needs less than one minute of hands-on work. [7][6]
Across more than 1,200 patients, the SEPSIS-SHIELD study found high sensitivity and specificity. TriVerity distinguishes bacterial infection, viral infection, and noninfectious inflammation while predicting illness severity. [10]
Research across several datasets found four immune-response groups. Patients in the dysfunctional groups were five to seven times more likely to die or need intensive care. [6]
Inflammatix is also building host-response tests for emerging infectious diseases and autoimmune disease. Other pipeline areas include tropical infections and transplant rejection. [2]
Use of Funds
Milestones
Scroll table to see all columns →
| Date | What happened | Source | Coverage |
|---|---|---|---|
| Oct 14, 2026 | BARDA awarded Inflammatix a $1 million development contract for Project Compass. The project will test TriVerity as a predictor of corticosteroid response. | [5] | — |
| Oct 8, 2026 | Inflammatix was selected for the ARPA-H CIRCLE program focused on precision immune medicine in intensive care. | [8] | — |
| Jun 16, 2026 | Inflammatix partnered with the University of Nebraska Medical Center on a TriVerity response to a hantavirus outbreak. | [5] | — |
| Sep 30, 2025 | Inflammatix announced three Nature Medicine publications on acute-infection and sepsis diagnosis and treatment. | [6] | — |
| Aug 4, 2025 | CMS granted TriVerity New Technology Add-On Payment reimbursement for fiscal 2026. | [9] | — |
| Mar 25, 2025 | Inflammatix shipped TriVerity cartridges and Myrna instruments to the U.S. military. | [5] | — |
| Jan 2025 | FDA granted TriVerity 510(k) clearance. | [6] | — |
| 2024 | Inflammatix submitted a TriVerity regulatory packet to FDA. | [7] | — |
| Nov 2023 | FDA granted Breakthrough Device Designation to TriVerity. | [7] | — |
We wrote this summary from public statements by Inflammatix and its investors. It is not investment advice.
Sources
- CompanyInflammatix home page · linked above ↑
- CompanyInflammatix company and team
- CompanyInflammatix contact page
- CompanyInflammatix terms and conditions
- CompanyInflammatix newsroom
- CompanyInflammatix Nature Medicine announcement
- CompanyInflammatix Series E announcement
- CompanyInflammatix CIRCLE program announcement
- PressTriVerity reimbursement release
- PressInflammatix Nature Medicine wire release
- SECInflammatix Form D, filed 2026-11-19 · linked above ↑
- SECInflammatix Form D, filed 2021-03-24 · linked above ↑
- SECInflammatix Form D, filed 2020-02-03 · linked above ↑
- SECINFLAMMATIX, INC. filing history
